Auro Laboratories Posts 92% Profit Growth on 58% Revenue Jump for FY26

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Auro Laboratories Posts 92% Profit Growth on 58% Revenue Jump for FY26
Overview

Auro Laboratories reported strong financial results for FY26, with revenue up 58.45% and net profit soaring 91.85%. The company also appointed Nitesh Bohra as its new CFO.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Auro Laboratories FY26 Performance Boosted by Strong Growth, New CFO Appointed

Revenue: ₹30.74 crore (Year ended March 31, 2026)
Net Profit: ₹3.53 crore (Year ended March 31, 2026)

Reader Takeaway: Robust revenue and profit growth evident; watch regulatory cost impact.

What just happened

Auro Laboratories Limited announced its financial results for the fiscal year ended March 31, 2026. The company reported a significant year-over-year increase in both revenue and net profit. Revenue from operations surged by 58.45% to ₹30.74 crore, up from ₹19.40 crore in the previous fiscal year. Net profit after tax also saw a substantial jump of 91.85%, reaching ₹3.53 crore compared to ₹1.84 crore in FY25.

Additionally, the company announced the appointment of Mr. Nitesh Bohra as its new Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective May 29, 2026. Mr. Bohra brings over two decades of experience in financial management, banking, auditing, and taxation.

The company also received an unmodified audit opinion, indicating confidence in its financial reporting. However, the implementation of new Labour Codes resulted in an incremental impact of ₹0.1442 crore on annual results due to a gratuity provision.

Why this matters

The strong financial performance indicates healthy business expansion and improved profitability for Auro Laboratories. The appointment of an experienced CFO suggests a strengthening of the company's financial leadership. While a one-time regulatory compliance cost has impacted the profit figures, the overall trend points towards a positive financial trajectory for the company.

The backstory

In the previous fiscal year, FY25, Auro Laboratories had reported revenue of ₹19.40 crore and a net profit of ₹1.84 crore. The current fiscal year's results show a significant acceleration in growth.

What changes now

The appointment of Mr. Nitesh Bohra as CFO is the most immediate change, bringing new financial leadership to the company. Investors will be keen to see how this new leadership navigates future financial strategies and operations.

Risks to watch

The primary watch point is the ongoing impact of regulatory changes, specifically the new Labour Codes. The provision for gratuity, though a one-time impact, highlights the potential for compliance costs to affect profitability. Investors should monitor future financial statements for any recurring effects or new regulatory challenges.

Peer comparison

(No peer comparison data provided in the filing)

Context metrics

  • Revenue from Operations (FY26): ₹30.74 crore (₹3,073.98 lakh)
  • Net Profit after Tax (FY26): ₹3.53 crore (₹353.29 lakh)
  • Revenue from Operations (Q4 FY26): ₹9.83 crore (₹983.25 lakh)
  • Net Profit after Tax (Q4 FY26): ₹0.97 crore (₹97.07 lakh)

What to track next

Investors should track the company's future quarterly and annual results to see if the strong growth momentum continues. Monitoring the effective integration of the new CFO and their strategic contributions will also be crucial. Additionally, understanding the longer-term financial implications of the new Labour Codes will be important.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.